A new funder is backing a shareholder class action that will be brought against Australian regenerative medicine company Mesoblast over disclosures related to its Remestemcel-L treatment for COVID-19 complications.
The Australian Competition and Consumer Commission has raised concerns about a proposed takeover of NSW-based pet drug maker Jurox by US animal health giant Zoetis.
A group of nurses have dropped their lawsuit against Monash Health alleging the hospital provider threatened to take adverse action against them for failing to get vaccinated against COVID-19.
Bristol-Myers Squibb has agreed to open up its subsidised treatment program for stage IV melanoma patients to individuals who have been treated with drugs made by its competitors to settle a misuse of market power lawsuit brought by rival Merck Sharpe & Dohme.
IP Australia has quashed an extension for a patent covering a Bayer oral contraceptive, saying the extension should have been calculated based on a drug that was included on the Australian Register of Therapeutic Goods at an earlier date.
Rideshare giant Uber has lost its bid to prevent a Queensland-based healthcare app from registering its ‘Uberdoc’ trademark despite a “high degree of similarity” to a suite of Uber trade marks.
Astora Women’s Health says group members should accept an open $27 million settlement offer in a class action over its allegedly defective pelvic mesh devices, warning that “financial difficulties” may prevent it from meeting any judgment if the case succeeds at trial.
The Australian Competition and Consumer Commission is investigating claims by suppliers that government bodies have diverted supplies of COVID-19 rapid antigen tests, as the regulator continues its crackdown on reported price gouging amid a test shortage.
A judge has suggested that a class action against the New South Wales government over a mandate requiring healthcare workers to be vaccinated against COVID-19 should be de-classed, saying it was a “straightforward point” because no financial relief was sought.
Israeli drug company Neurim Pharmaceuticals has won an eight month extension to apply for a grace period for its melatonin tablet patent to treat children with autism spectrum disorder after Australian company Generic Partners lost its “inherently implausible” opposition to the patent.